Format

Send to

Choose Destination
Autoimmun Rev. 2014 Jul;13(7):699-707. doi: 10.1016/j.autrev.2014.03.002. Epub 2014 Mar 20.

14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome.

Author information

1
Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Catalonia, Spain. Electronic address: rcervera@clinic.cat.
2
Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Catalonia, Spain.
3
Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Rome, Italy.
4
Internal Medicine Department, Hospital de Pedro Hispano, Matosinhos, Portugal.
5
The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Israel.
6
The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Israel; Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Tel-Aviv University, Israel.
7
Unidade de Imunologia Clínica, Hospital Santo António, Centro Hospitalar do Porto, ICBAS, Instituto Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal.
8
Hospital Universitário Pedro Ernesto, Universidade do Estado do Rio de Janeiro, Brazil.

Abstract

The 'Task Force on Catastrophic Antiphospholipid Syndrome (CAPS)' was developed on the occasion of the 14th International Congress on Antiphospholipid Antibodies. The objectives of this Task Force were to assess the current knowledge on pathogenesis, clinical and laboratory features, diagnosis and classification, precipitating factors and treatment of this condition in order to address recommendations for future research. This article summarizes the studies analyzed by the Task Force, its recommendations and the future research agenda.

PMID:
24657970
DOI:
10.1016/j.autrev.2014.03.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center